Research programme: protein misfolding disease therapeutics - Chaperone Therapeutics/Senhwa Biosciences

Drug Profile

Research programme: protein misfolding disease therapeutics - Chaperone Therapeutics/Senhwa Biosciences

Alternative Names: Therapeutics for proteopathies - Chaperone Therapeutics/Senhwa Biosciences

Latest Information Update: 14 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Senhwa Biosciences
  • Developer Chaperone Therapeutics; Senhwa Biosciences
  • Class Small molecules
  • Mechanism of Action Protein folding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glycogen storage disease type I; Hearing loss; Neurodegenerative disorders

Most Recent Events

  • 14 Dec 2016 Preclinical trials in Glycogen storage disease type I in USA
  • 14 Dec 2016 Preclinical trials in Hearing loss in USA
  • 04 Sep 2015 Preclinical trials in Neurodegenerative disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top